{"DataElement":{"publicId":"2724331","version":"1","preferredName":"Agent Adverse Event Attribution Name","preferredDefinition":"the names as related to agent attributed for any unfavorable or unintended symptom, sign, or disease including an abnormal laboratory finding) temporally attributed to an agent.","longName":"AGT_AE_ATTR_NAME","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2724329","version":"1","preferredName":"Agent Adverse Event Attribution","preferredDefinition":"information related to an agent to is attributed for any unfavorable or unintended symptom, sign, or disease including an abnormal laboratory finding) temporally.","longName":"AGT_AE_ATTRIB","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2223333","version":"1","preferredName":"Agent","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F62B10F2-76A7-2830-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2547786","version":"1","preferredName":"Adverse Event Attribution","preferredDefinition":"Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used.:assigning to a cause or source.","longName":"C41331:C25358","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adverse Event","conceptCode":"C41331","definition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Attribution","conceptCode":"C25358","definition":"To assign to a cause or source.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2363D581-0167-398C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-11-29","modifiedBy":"ONEDATA","dateModified":"2006-11-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"443FC341-3097-3B76-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2008-01-21","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2724324","version":"1","preferredName":"Agent Attribution Name","preferredDefinition":"the words or language units by which a thing is known for an agent used for treating disease.","longName":"AGT_ATTR_NAM","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Cytarabine","valueDescription":"Cytosine Arabinoside","ValueMeaning":{"publicId":"2724325","version":"1","preferredName":"Cytosine Arabinoside","longName":"2724325","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"443FAAF5-4136-370B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALAIS","dateCreated":"2008-01-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"443FAAF5-414F-370B-E044-0003BA3F9857","beginDate":"2008-01-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2008-01-21","modifiedBy":"ALAIS","dateModified":"2008-01-21","deletedIndicator":"No"},{"value":"Daunorubicin","valueDescription":"Daunorubicin","ValueMeaning":{"publicId":"2724326","version":"1","preferredName":"Daunorubicin","longName":"2724326","preferredDefinition":"An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daunorubicin","conceptCode":"C62091","definition":"An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"443FAAF5-415D-370B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALAIS","dateCreated":"2008-01-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"443FAAF5-4176-370B-E044-0003BA3F9857","beginDate":"2008-01-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2008-01-21","modifiedBy":"ALAIS","dateModified":"2008-01-21","deletedIndicator":"No"},{"value":"Midostaurin/Placebo","valueDescription":"Midostaurin/Placebo","ValueMeaning":{"publicId":"2724332","version":"1","preferredName":"Midostaurin/Placebo","longName":"2724332","preferredDefinition":"Protein kinase C412 (Midostaurin) is an oral multitargeted kinase inhibitor/Placebo (An inactive substance or preparation used as a control in an experiment or test to determine the effectiveness of a medicinal drug) ","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"443FDD62-E1DC-4068-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2008-01-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"443FDE34-9D01-3E86-E044-0003BA3F9857","beginDate":"2008-01-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2008-01-21","modifiedBy":"ONEDATA","dateModified":"2008-01-21","deletedIndicator":"No"},{"value":"Bevacizumab/Placebo","valueDescription":"Placebo Bevacizumab","ValueMeaning":{"publicId":"2823335","version":"1","preferredName":"Placebo Bevacizumab","longName":"2823335","preferredDefinition":"An inactive substance, treatment or procedure that is intended to mimic as closely as possible a therapy in a clinical trial.: A monoclonal antibody that may prevent the growth of blood vessels from surrounding tissue to a solid tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"604C2313-B7C6-101A-E040-BB89AD43675B","latestVersionIndicator":"Yes","beginDate":"2009-01-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"604C2313-B7DF-101A-E040-BB89AD43675B","beginDate":"2009-01-12","endDate":null,"createdBy":"CDECURATE","dateCreated":"2009-01-12","modifiedBy":"CDECURATE","dateModified":"2009-01-12","deletedIndicator":"No"},{"value":"Letrozole/Tamoxifen","valueDescription":"Tamoxifen Letrozole","ValueMeaning":{"publicId":"2823336","version":"1","preferredName":"Tamoxifen Letrozole","longName":"2823336","preferredDefinition":"An antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).  Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA.  The result is a reduction in DNA synthesis and cellular response to estrogen.  In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. (NCI04): A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tamoxifen Citrate","conceptCode":"C855","definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Letrozole","conceptCode":"C1527","definition":"A nonsteroidal inhibitor of estrogen synthesis with antineoplastic activity. As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent breast cancer cells. Aromatase, a cytochrome P-450 enzyme localized to the endoplasmic reticulum of the cell and found in many tissues including those of the premenopausal ovary, liver, and breast, catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"604C2313-B7EE-101A-E040-BB89AD43675B","latestVersionIndicator":"Yes","beginDate":"2009-01-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"604C2313-B807-101A-E040-BB89AD43675B","beginDate":"2009-01-12","endDate":null,"createdBy":"CDECURATE","dateCreated":"2009-01-12","modifiedBy":"CDECURATE","dateModified":"2009-01-12","deletedIndicator":"No"},{"value":"Interferon","valueDescription":"Interferon","ValueMeaning":{"publicId":"3119698","version":"1","preferredName":"Interferon","longName":"3119698","preferredDefinition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon","conceptCode":"C20493","definition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AE1E2A1-466C-6C31-E040-BB89AD434C6B","latestVersionIndicator":"Yes","beginDate":"2010-07-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-08","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"09B95C5D-1C5D-87C6-E050-BB89AD4338B5","beginDate":"2014-12-08","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-12-08","modifiedBy":"ONEDATA","dateModified":"2014-12-08","deletedIndicator":"No"},{"value":"Indeterminant","valueDescription":"Indeterminant","ValueMeaning":{"publicId":"4592211","version":"1","preferredName":"Indeterminant","longName":"4592211","preferredDefinition":"Indeterminant","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"07C3981A-FB9E-ADEA-E050-BB89AD432AE9","latestVersionIndicator":"Yes","beginDate":"2014-11-13","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-11-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"07C3981A-FBB7-ADEA-E050-BB89AD432AE9","beginDate":"2014-11-13","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-11-13","modifiedBy":"ONEDATA","dateModified":"2014-11-13","deletedIndicator":"No"},{"value":"Both","valueDescription":"Both","ValueMeaning":{"publicId":"2558322","version":"1","preferredName":"Both","longName":"2558322","preferredDefinition":"Two entities considered and identifed together.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Both","conceptCode":"C49636","definition":"One and the other; relating to or being two in conjunction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B0DF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"REEVESD","dateModified":"2009-12-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"07C3981A-FBC1-ADEA-E050-BB89AD432AE9","beginDate":"2014-11-13","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-11-13","modifiedBy":"ONEDATA","dateModified":"2014-11-13","deletedIndicator":"No"},{"value":"Ipilimumab","valueDescription":"Ipilimumab","ValueMeaning":{"publicId":"3185135","version":"1","preferredName":"Ipilimumab","longName":"3185135","preferredDefinition":"A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipilimumab","conceptCode":"C2654","definition":"A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A2F1-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"07C3981A-FBCB-ADEA-E050-BB89AD432AE9","beginDate":"2014-11-13","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-11-13","modifiedBy":"ONEDATA","dateModified":"2014-11-13","deletedIndicator":"No"},{"value":"Bevacizumab","valueDescription":"Bevacizumab","ValueMeaning":{"publicId":"2574306","version":"1","preferredName":"Bevacizumab","longName":"2574306","preferredDefinition":"A monoclonal antibody that may prevent the growth of blood vessels from surrounding tissue to a solid tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF4F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"ALAIS","dateModified":"2006-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"07C3981A-FBD5-ADEA-E050-BB89AD432AE9","beginDate":"2014-11-13","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-11-13","modifiedBy":"ONEDATA","dateModified":"2014-11-13","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"443FAA61-4C23-3499-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2008-01-21","modifiedBy":"ROUILLAS","dateModified":"2014-12-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811913","version":"1","longName":"Lymphoma","context":"CTEP"},{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811951","version":"1","longName":"Adverse Events","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000362","version":"1","longName":"AML Prev Untreated","context":"CTEP"}]},{"publicId":"2008608","version":"1","longName":"Phase","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811890","version":"1","longName":"Phase III","context":"CTEP"}]}],"AlternateNames":[{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"}],"ReferenceDocuments":[{"name":"Attributable to which medicat","type":"Preferred Question Text","description":"Attributable to which medication","url":null,"context":"CTEP"},{"name":"ECOG CRF Text 1","type":"Alternate Question Text","description":"Which agent is the AE more likely attributed to?","url":null,"context":"ECOG-ACRIN"}],"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"443FCA28-F2F8-3CF6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2008-01-21","modifiedBy":"ROUILLAS","dateModified":"2014-11-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}